Noxopharm announces major survival benefit in prostate cancer patients
Australian clinical-stage drug development company Noxopharm surged 21% on Tuesday after it published the latest survival data from its LuPIN study ahead of a formal presentation to the American Society of Clinical Oncology Genitourinary Cancers Symposium, the pre-eminent medical conference dedicated to sharing the most recent innovations in the treatment of genitourinary cancers.
Noxopharm claims the data demonstrates the emergence of a major new treatment for prostate cancer. The LuPIN drug combination of Veyonda and Lu-PSMA-617 (Novartis) results in half of all patients surviving at least 19.7 months, a ground-breaking outcome for men with end-stage (Stage 4) disease and no remaining treatment options.
Noxopharm is undertaking strategic discussions with respect to making LuPIN treatment a new standard of care, as the survival benefit exceeds that reported for any current standard of care treatment including one acquired by Pfizer in 2016 for US$14 billion.
A team of eminent medical researchers from Sydney’s St Vincent’s Hospital and Melbourne’s Peter MacCallum Cancer Centre and led by Professor Louise Emmett conducted the independent Phase I/II study. They reported that Veyonda was safe and efficacious in combination with 177Lu-PSMA-617, an experimental radiopharmaceutical acquired by the major Swiss pharma company, Novartis, three years ago for US$6 billion across a series of transactions.
Noxopharm CEO, Dr Graham Kelly, said, “This data has been generated in an independent study and is being shared on the world stage by leading Australian researchers. The reported median overall survival is an extraordinary outcome and easily exceeds that obtained with any of the current treatments for Stage 4 prostate cancer in their registration studies. That difference is even more remarkable when you consider that those other treatments were tested in men with considerably less advanced disease than those in the LuPIN study.”